Tango Therapeutics draws fresh attention after $618,000 insider sale
Tango Therapeutics shares traded up 1.8% at $21.86 during Thursday afternoon hours. The cancer-drug maker stayed close to its highs after a new filing disclosed the company’s research chief had sold stock using a preset trading plan. The SPDR S&P Biotech ETF climbed 2.6%. Tango is a popular small-cap biotech trade, and the latest move has some impact. Shares are up around 149% this year, according to MarketBeat. Every insider filing and update on the company’s main cancer program has some effect as a result.